{"changes":[],"country":"US","description":"Discovers small-molecule cancer drugs including BH-30643, a mutant-selective OMNI-EGFR inhibitor, and BH-30236, a CLK inhibitor for relapsed AML and MDS. Built for patients with EGFR/HER2-mutant NSCLC and high-risk hematologic cancers. Co-founded by J. Jean Cui, the chemist behind crizotinib, lorlatinib and repotrectinib, with $257M raised to date.","domain":"blossomhilltx.com","employees":null,"founded":2020,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":32.71742,"lng":-117.162772,"location":"San Diego, USA","name":"BlossomHill Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":84000000,"currency":"USD","date":"2025-12-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-17","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"blossomhilltx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-17","status":"attributed","url":null},{"fact":"existence","publisher":"blossomhilltx.com","retrievedAt":"2026-05-17","status":"self-reported","url":"https://blossomhilltx.com"},{"fact":"description","publisher":"blossomhilltx.com","retrievedAt":"2026-05-17","status":"self-reported","url":"https://blossomhilltx.com"}],"stage":"series-b+","techStack":[],"totalRaisedUsd":257000000,"updatedAt":"2026-05-17"}